MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games

gene therapy

  • Home
  • gene therapy
  • Page 2
OTOF Gene Therapy Rivaled—and in Some Domains Outperformed—Cochlear Implants in Restoring Hearing and Speech in Congenital Deafness
Posted innews Otorhinolaryngology Pediatrics

OTOF Gene Therapy Rivaled—and in Some Domains Outperformed—Cochlear Implants in Restoring Hearing and Speech in Congenital Deafness

Posted by By MedXY 11/04/2025
A 2022–2024 nonblinded cohort study found OTOF gene therapy produced rapid, durable gains in auditory thresholds, speech perception, mismatch-negativity responses, and music perception versus cochlear implantation in children with genetically driven congenital deafness.
Read More
DB-OTO Restores and Sustains Hearing in Otoferlin-Deficient Mice: A Hair-Cell–Targeted Dual-AAV Strategy Advances to Clinical Testing
Posted innews Otorhinolaryngology Pediatrics

DB-OTO Restores and Sustains Hearing in Otoferlin-Deficient Mice: A Hair-Cell–Targeted Dual-AAV Strategy Advances to Clinical Testing

Posted by By MedXY 11/04/2025
DB-OTO, a hair-cell-specific dual-AAV gene therapy encoding full-length human otoferlin, achieved dose-dependent and sustained auditory restoration in OTOF-deficient mice, supporting an ongoing Phase I/II pediatric trial.
Read More
Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency
Posted inAllergy & Immunology Hematology-Oncology news

Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency

Posted by By MedXY 10/25/2025
This study demonstrates the long-term effectiveness and safety of autologous gene therapy for treating ADA deficiency, showing sustained immune function and minimal adverse effects over a median follow-up of 7.5 years.
Read More
DB-OTO Gene Therapy: A Breakthrough Treatment for OTOF-Related Inherited Deafness in Children
Posted innews Otorhinolaryngology Pediatrics

DB-OTO Gene Therapy: A Breakthrough Treatment for OTOF-Related Inherited Deafness in Children

Posted by By MedXY 10/24/2025
Regeneron's DB-OTO gene therapy shows promising results in restoring natural hearing in children with profound hearing loss caused by OTOF gene mutations, with 75% achieving significant hearing improvement after a single treatment.
Read More
Advances in Targeted and Gene Therapies: Promising Data on KRAS G12D Inhibitors, DR5 Agonists, and Ocular Gene Therapy
Posted inHematology-Oncology news Ophthalmology

Advances in Targeted and Gene Therapies: Promising Data on KRAS G12D Inhibitors, DR5 Agonists, and Ocular Gene Therapy

Posted by By MedXY 10/24/2025
Recent clinical trials report encouraging tumor shrinkage with KRAS G12D inhibitor VS-7375, significant progression-free survival benefit in soft tissue sarcoma with ozekibart, and a novel gene therapy acquisition targeting wet AMD.
Read More
Prademagene Zamikeracel: A Breakthrough Gene Therapy for Chronic Wounds in Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Posted inAllergy & Immunology Clinical Updates Dermatology Pediatrics Specialties

Prademagene Zamikeracel: A Breakthrough Gene Therapy for Chronic Wounds in Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Posted by By MedXY 08/02/2025
A phase 3 trial demonstrates prademagene zamikeracel significantly accelerates healing and reduces pain in large, chronic RDEB wounds, offering a promising gene therapy with a favorable safety profile.
Read More
Haematopoietic Gene Therapy Without Conditioning for Fanconi Anaemia-A: Results and Clinical Implications from the FANCOLEN-1 Trials
Posted inClinical Updates Hematology-Oncology news Specialties

Haematopoietic Gene Therapy Without Conditioning for Fanconi Anaemia-A: Results and Clinical Implications from the FANCOLEN-1 Trials

Posted by By MedXY 08/02/2025
Gene therapy using autologous, gene-corrected stem cells without conditioning offers sustained engraftment and reverses bone marrow failure in Fanconi anaemia-A, with a favorable safety profile.
Read More
Durable Efficacy and Long-term Safety of AAV Gene Therapy in Severe Hemophilia B: 13-Year Follow-up Results
Posted inClinical Updates Hematology-Oncology news Specialties

Durable Efficacy and Long-term Safety of AAV Gene Therapy in Severe Hemophilia B: 13-Year Follow-up Results

Posted by By MedXY 08/01/2025
A single AAV gene therapy infusion for severe hemophilia B led to sustained factor IX expression, substantial reduction in bleeding and factor use, and no late safety concerns over 13 years.
Read More

Posts pagination

Previous page 1 2

Take a game break

Explore a few games from MedXY.

Explore all games
  • Early Controlled Mobilisation in Radial Head Fractures Enhances Recovery Without Clinically Significant Differences
  • Innovative Polyurethane Resin Cement with Dual Antibacterial Mechanisms for Enhanced Secondary Caries Prevention
  • Remibrutinib Demonstrates Superior Efficacy and Safety over Teriflunomide in Relapsing Multiple Sclerosis: Insights from REMODEL-1 and REMODEL-2 Phase 3 Trials
  • The Community Pediatrics & Advocacy Curriculum: Standardizing Advocacy Education in Pediatric Graduate Medical Education
  • Sustained Remission and Long-Term Success: A Decade of Treat-to-Target Therapy in Early Rheumatoid Arthritis
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation machine learning MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top